[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"magnetic-resonance-imaging-mri\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:magnetic-resonance-imaging-mri":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,70,100,125,150,175,211,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100619448","new-simulation-care-pathway-for-paediatric-mri-preparation-100619448",false,"NCT07344753","New Simulation Care Pathway for Paediatric MRI Preparation","20 000 Lieues Sous l'IRM - New Simulation Care Pathway for Paediatric MRI Preparation : Exploratory Descriptive Pilot Study","Inclusion criteria\n\n* Children aged 36 to 72 months scheduled to undergo an MRI scan\n* Consent obtained from the child and their parent or legal guardian\n* Patient affiliated with the social security system, CMU\n* Children who has not had an MRI since the age of 10 months Exclusion criteria\n* Children who are completely hostile to the experience.\n* Children with cognitive or behavioural disorders.\n* Children or parents\u002Fguardians who do not understand French.\n* Children coming to validate the fitting of a cochlear implant","ALL","36 Months","72 Months",{"count":20,"type":21},114,"ESTIMATED","OBSERVATIONAL","Magnetic resonance imaging (MRI) is a common imaging procedure that is safe and non-invasive, as it relies on the use of different magnetic fields. It is the gold standard examination for a wide range of pathologies.\n\nHowever, it has many disadvantages, including the repetitive noise produced by the coils during image acquisition sequences, which can cause discomfort. The noise level often exceeds 100 dB, while the noise exposure limit for workers is set at 87 dB. There is no regulatory limit for patients. Although it is relatively loud and quite unpleasant, this noise is not harmful to health and does not amplify, contrary to the perception that one may have in the tunnel. Noise-cancelling headphones and earbuds are strongly recommended for patients to reduce any discomfort that may result. In practice, the imaging department requires all patients to wear hearing protection.\n\nOther disadvantages of MRI include confinement in a tunnel and the need to remain completely immobile for approximately six sequences, each of 2 to 5 minutes in duration.\n\nThis can be problematic, particularly for patients suffering from pain or respiratory failure, or for agitated individuals who find it difficult to remain motionless in a lying position for long periods of time.\n\nThese various issues are particularly relevant in the paediatric population, for whom MRI is the preferred imaging technique due to its safety in terms of radiation exposure.\n\nThe specific characteristics of this population require more complex patient management due to the particular constraints of MRI. Acceptance of the following four points appears to be key to its successful implementation: lying down, with the head in a tunnel, intense and repeated noises, and strict immobility for at least 30 minutes. Without these conditions, the images recorded will not provide reliable results that can be used for diagnosis.\n\nTo meet these constraints, at Nantes University Hospital, general anaesthesia was routinely administered to children aged 3 to 6 until September 2023. This ensures a 100% success rate for the examination, but it is not a trivial procedure for the child and is stressful for their parents. Since then, a light sedation protocol has been offered as part of the care pathway. This involves the child taking medication one hour and then thirty minutes before the MRI scan to calm them down until they fall asleep.\n\nUnfortunately, access to this MRI under light sedation or general anaesthesia complicates the appointment booking process, as it requires the presence of a medical team during dedicated shifts.\n\nMRI scans under light sedation are scheduled for three slots per week. At the end of 2025, the waiting time was four months for light sedation and six months for general anaesthesia.\n\nIn order to improve and speed up the care of children who need to perform an MRI scan, a specific consultation with an immersive four-module programme has been designed at Nantes University Hospital with the aim of optimising the chances of success of the examination without general anaesthesia or sedation, thereby:\n\n* Reduce waiting times for appointments, and thus reduce the period of stress for parents awaiting a diagnosis for their child.\n* Reduce the time required for the examination. Indeed, an examination under light sedation considerably lengthens the treatment time, with a sedation onset time of approximately 1.5 hours.\n* Increasing the success rate of MRI scans under light sedation following failure without sedation.\n\nThis innovative approach is based on an immersive experience in the form of a course consisting of four modules designed to help children practise four areas that can be challenging for them (immersion in a tunnel, loud noise, the constraints of specific equipment, and immobility). These modules are themed around the marine world, in line with the already approved paediatric radiology programme. It will be offered to children aged 3 to 6 with no cognitive or behavioural disorders.\n\nThe modules will be installed in a paediatric consultation room and will be used for half a day each month. When not needed, they'll be put away so the room can be used for consultations.\n\nThe aim of our pilot study is to assess the impact of this immersive journey on the success of an MRI scan without general anaesthesia or sedation.",[25],"Magnetic Resonance Imaging (MRI)",[25,27,28],"Immersive experience","Paediatric MRI","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-02-11",{"date":37,"type":21},"2028-08-15",{"name":39,"class":40},"Nantes University Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100633535","pastrami--patient-specific-statistics-for-microstructure-augmented-connectomics-100633535","NCT07527949","PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics","PASTRAMI","Inclusion Criteria:\n\n1. Aged 18 to 60\n2. Admitted for moderate to severe non-penetrating head injury (with a Glasgow Coma Scale score ≤ 12)\n3. On mechanical ventilation and under continuous sedation\n4. Enrolled in a social security program\n5. Whose family has been informed and has signed a voluntary, informed, written consent form\n\nExclusion Criteria:\n\n1. History of head trauma, stroke, or neurodegenerative diseases\n2. A decision to limit active treatment has already been made\n3. Quadriplegia\n4. Contraindications to MRI\n5. Protected individuals (adults under legal protection \\[judicial protection, guardianship, conservatorship\\], individuals deprived of liberty, pregnant women \\[self-reported\\], breastfeeding women, and minors).","18 Years","60 Years",{"count":52,"type":21},100,"INTERVENTIONAL",[55],"NA","Traumatic brain injury (TBI) represent a major public health issue, accounting for approximately 1.5 million hospital admissions annually across the European Union and 160,000 cases in France. They are a significant cause of mortality and disability, with serious consequences for patients and their families. Predicting functional outcomes remains complex due to the heterogeneity of brain injuries, whether primary or secondary, as well as the mechanisms involved, particularly neuroinflammation. This difficulty is particularly pronounced for moderate to severe TBI, for which current predictive tools are still limited.\n\nThe PASTRAMI project proposes to utilise diffusion magnetic resonance imaging (MRI) to identify biomarkers associated with axonal lesions in the white matter. This technique enables the analysis of brain microstructure and the reconstruction of neural connections (connectome), thereby offering innovative prospects for improving the prediction of functional recovery.\n\nThis is a prospective, multicentre, interventional study involving 100 patients aged between 18 and 60 years with moderate to severe traumatic brain injury. The primary objective is to assess the prognostic value of brain microstructural measures at baseline, by correlating them with the GOSE functional score at 1 year. Secondary objectives include the analysis of mortality, functional outcome, quality of life, and early physiological factors influencing progression.\n\nPatients will undergo a standard MRI scan supplemented with additional sequences for prognostic purposes, without any change to their therapeutic management. The associated risks are minimal and relate primarily to the MRI scan. No immediate individual benefit is expected, but the results could improve our understanding of brain lesions and optimise future management.\n\nThe total duration of the study is 48 months. The expected outcomes include better characterisation of lesions and improved predictive tools, contributing to more appropriate clinical decisions.",[58,25],"Traumatic Brain Injury","NOT_YET_RECRUITING","2026-06-11",{"date":62,"type":33},"2026-06-12",{"date":64,"type":21},"2026-09-01",{"date":66,"type":21},"2030-09-01",{"name":68,"class":40},"Rennes University Hospital",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100643796","non-contrast-breast-mri-diagnosis-and-risk-stratification-using-dwi-generated-synthetic-contrast-enhancement-100643796","NCT07598084","Non-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast Enhancement","Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI: Development and Clinical Validation of a Diffusion-Weighted Imaging-Based Synthetic Contrast-Enhanced MRI System for Non-Contrast Breast Cancer Diagnosis and Risk Stratification","Inclusion Criteria:\n\n1. Complete breast MRI data;\n2. Negative pathology biopsy results or negative follow-up examinations for at least 12 months for non-cancer cases;\n3. Positive biopsy results that meet the requirements for the pathological subtype of cancer for cancer cases;\n4. Original data that can be used to verify clinical status, including radiological and pathological reports;\n\nExclusion Criteria:\n\n1. Partial mastectomy or puncture biopsy on the diseased side of the breast prior to breast MRI examination;\n2. Poor image quality;\n3. Implants in the affected breast;",true,{"count":79,"type":21},12000,"This study is conducted under the ethics-approved project titled \"Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI''.The goal of this observational study is to develop an integrated breast MRI system that uses diffusion-weighted imaging (DWI) to create synthetic contrast-enhanced images. This system aims to diagnose and screen for breast cancer without the need for contrast agents, while using a generated risk score to perform imaging-based triage and risk stratification.\n\nParticipants will include people aged 18 and older who require a breast MRI either for evaluation of a suspicious finding or for high-risk screening.\n\nThis study seeks to answer two main questions:\n\n* Can synthetic contrast-enhanced images generated from DWI match real contrast-enhanced images in their ability to distinguish benign from malignant breast lesions?\n* Can the risk score derived from DWI-based synthetic images enable imaging-level risk stratification, allowing people at lower risk to avoid contrast agent injection? Researchers will compare the quality of synthetic images against real contrast-enhanced images and will recruit radiologists to assess how well these images perform for diagnostic and screening tasks. MRI data from participants undergoing breast MRI will be used to train, validate, and test this integrated system.",[82,83,25,84,85],"Breast Neoplasms","Artificial Intelligence (AI)","Diffusion Magnetic Resonance Imaging","Deep Learning",[87,88,89,90],"Breast","Magnetic Resonance Imaging","Artificial Intelligence","Deep learning","2026-06-05",{"date":93,"type":33},"2026-06-09",{"date":95,"type":21},"2026-06",{"date":97,"type":21},"2027-05",{"name":99,"class":40},"Peking University People's Hospital",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":77,"sex":16,"minAge":49,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":53,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100620397","carbon-dioxide-administration-and-brain-waste-clearance-100620397","NCT07357090","Carbon Dioxide Administration and Brain Waste Clearance","Mechanisms Underlying Carbon Dioxide Induced Protein Efflux in Health and Traumatic Brain Injury","COPETBI","Inclusion criteria for TBI cohort: 1) Able to give valid informed consent, 2) 18-82 years old, 3) history of TBI of any severity level (mild, moderate or severe) that was sustained in adulthood (age 18 and older), which will be confirmed using a semi-structured identification method (includes asking about loss of consciousness, posttraumatic amnesia, and feeling dazed\u002Fconfused).\n\nInclusion criteria for Healthy Subjects cohort: 1) Able to give valid informed consent and 2) 18-82 years old years old.\n\nExclusion criteria for TBI cohort: 1) contraindications to MRI scanning including pregnancy or claustrophobia, 2) unable to give valid informed consent, incarcerated, 3) diagnosed with Alzheimer's, ADRD or mild cognitive impairment, 4) pre-existing history of autism spectrum disorders, intellectual disability, serious neurological (e.g., epilepsy, tumors, other conditions requiring neurosurgery) or psychiatric disorders (requiring hospitalization) prior to TBI onset, 5) current or previous diagnosis of a psychosis spectrum disorder or bipolar disorder, 6) respiratory diseases or pulmonary conditions that may increase the risk of study procedures (e.g., severe asthma, chronic obstructive pulmonary disease or other significant respiratory disorders), 7) a history of cardiac arrythmias 8) history of a current substance use disorder, 9) non-English fluency (based on screener), 10) Weigh under 110 pounds for blood draw.\n\nExclusion criteria for Healthy Subjects cohort: 1) contraindications to MRI scanning including pregnancy or claustrophobia, 2) unable to give valid informed consent, incarcerated, 3) diagnosed with Alzheimer's, ADRD or mild cognitive impairment, 4) history of developmental, neurological, or psychiatric disorders requiring hospitalization, 5) regular use of any substance in the past six months (i.e., no current use confirmed with urine screening), 6) previous head injury with greater than 30 minutes loss of consciousness, 7) respiratory diseases or pulmonary conditions that may increase the risk of study procedures (e.g., severe asthma, chronic obstructive pulmonary disease or other significant respiratory disorders), 8) a history of cardiac arrythmias, 9) non-English fluency (based on screener), 10) Weigh under 110 pounds for blood draw.","82 Years",{"count":110,"type":21},200,[55],"The current study tests whether different exposures to carbon dioxide (CO2) can safely result in the increased movement of proteins from the brain into the blood. The investigators believe that this would be a proxy for the brain clearing waste products more effectively. The current study will use a counter-balanced design, in which individuals with and without a history of traumatic brain injury (TBI) will receive different levels of CO2 (targeted changes of approximately 5 or 10 mmHG in end-tidal CO2) approximately one week apart. The counter-balanced design means that each participant receives a single dose of CO2 at each visit, and different doses of CO2 at each visit. The order in which participants receive the dose is randomized, and the participant will not be informed of the dose.",[58,114,25],"Aging Disorder",[58,88],"2026-02-19",{"date":118,"type":33},"2026-02-23",{"date":120,"type":21},"2026-04",{"date":122,"type":21},"2032-02",{"name":124,"class":40},"Andrew Mayer",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":53,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":41},"100615762","internet-based-cognitive-behavioral-therapy-for-mri-related-anxiety-100615762","NCT07296822","Internet-Based Cognitive Behavioral Therapy for MRI-Related Anxiety","A Randomized Controlled Trial of Internet-Based Cognitive Behavioral Therapy for MRI-Related Anxiety","MRTightxiety","Inclusion Criteria:\n\n* self-perceived problems with doing MRI examinations\n\nExclusion Criteria:\n\n* difficulty understanding written text\n* severe mental health problems",{"count":134,"type":21},60,[55],"The aim of the study is to investigate whether internet-based cognitive behavioural therapy (iCBT) can help patients who have difficulty undergoing magnetic resonance imaging (MRI). The main question to be answered is\n\n\\- Can patients undergo MRI with less anxiety using iCBT?\n\nThe patients will undergo a four-week treatment that includes information about MRI, anxiety management, relaxation and retention. The end goal is to simulate an MRI scan in a mock scanner where participants can report their anxiety. Half of the participants will be randomized to receive the treatment before (intervention group) the simulated MRI scan and half will receive the treatment after the simulated MRI scan (control group). Up to 60 patients will be included plus some pilot patients.",[138,139,25],"Anxiety","Claustrophobia","2025-12-08",{"date":142,"type":33},"2025-12-22",{"date":144,"type":33},"2025-05-01",{"date":146,"type":21},"2026-12-31",{"name":148,"class":149},"Johan Kihlberg","OTHER_GOV",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":53,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100612384","interest-of-magnetic-resonance-imaging-in-the-diagnosis-of-upper-urinary-tract-invasive-tumours-100612384","NCT07252882","Interest of Magnetic Resonance Imaging in the Diagnosis of Upper Urinary Tract Invasive Tumours","UUTICaD","Inclusion Criteria:\n\n* Patient over 18 years of age with a suspected upper urinary tract tumour based on the presence of a suspicious lesion on a uro-computed tomography scan\n* Have given free, informed and signed consent\n* Be affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Renal failure not allowing the injection of iodinated contrast media (Glomerular filtration rate \\\u003C30mL\u002Fmin)\n* Subject under legal protection (guardianship or curatorship)\n* Pregnant or breastfeeding woman\n* Person participating in another research study or having participated in a protocol with an exclusion period still in progress at inclusion\n* Contraindication to magnetic resonance imaging (patient with non-magnetic resonance imaging compatible equipment, claustrophobia preventing magnetic resonance imaging)\n* Acide gadoteric hypersensibility",{"count":158,"type":21},178,[55],"Upper urinary tract invasive cancer magnetic resonance imaging diagnosis",[25,162],"Urologic Cancer",[164],"Upper urinary tract magnetic resonance imaging","2025-11-26",{"date":167,"type":33},"2025-11-28",{"date":169,"type":21},"2025-12-01",{"date":171,"type":21},"2027-12-31",{"name":173,"class":40},"University Hospital, Toulouse",11,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":183,"enrollmentInfo":184,"targetDuration":186,"studyType":22,"phases":4,"briefSummary":187,"conditions":188,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":41},"100598543","using-cardiac-mri-to-predict-outcomes-in-patients-with-stemi-100598543","NCT07072858","Using Cardiac MRI to Predict Outcomes in Patients With STEMI","Prognostic Value of Cardiac Magnetic Resonance Parameters in Patients With ST-Segment Elevation Myocardial Infarction","CMR-RISK-STEMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n\nDiagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels\n\nUnderwent primary percutaneous coronary intervention (PCI)\n\nAble to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI\n\nProvided written informed consent\n\nExclusion Criteria:\n\n* Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers)\n\nHistory of revascularization therapy (PCI or CABG) within the previous 6 months\n\nSevere valvular heart disease or known cardiomyopathy\n\nPresence of bundle branch block or fascicular block that interferes with image interpretation\n\nKnown allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences)\n\nEstimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² (if contrast use is anticipated)\n\nPregnant or breastfeeding women","80 Years",{"count":185,"type":21},1000,"5 Years","This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study integrates advanced artificial intelligence (AI) techniques to extract and analyze high-dimensional imaging features from multiple CMR sequences-including cine, strain mapping, and functional sequences-going beyond traditional measures such as infarct size or microvascular obstruction.\n\nThe primary objective is to identify novel prognostic markers from routinely acquired CMR images that reflect myocardial structure, function, and mechanical deformation (strain), and to assess their association with long-term clinical outcomes. In addition to standard parameters, the study includes a detailed evaluation of left and right ventricular systolic and diastolic volumes, ejection fractions, and biventricular strain components (including longitudinal, circumferential, and radial strain), as well as left and right atrial volumes, emptying fractions, and reservoir\u002Fconduit\u002Fbooster strain indices.\n\nApproximately 1000 STEMI patients will undergo CMR scanning within one week after PCI. The imaging data will be subjected to AI-based feature extraction and dimensionality reduction algorithms to uncover latent patterns associated with adverse outcomes. Patients will be followed for up to three years for the occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, recurrent myocardial infarction, and heart failure hospitalization.\n\nThe central hypothesis is that comprehensive CMR functional and strain-derived parameters, when analyzed using AI-driven models, offer independent and incremental prognostic value beyond conventional clinical risk factors. This study seeks to establish a data-driven, multimodal imaging framework for personalized risk stratification in STEMI patients, potentially enabling more precise post-infarction management strategies.\n\nNo investigational treatment is involved. All imaging and clinical data are collected as part of routine care and analyzed retrospectively for outcome prediction.",[189,190,25,191,83,192,193],"Myocardial Infarction (MI)","ST Segment Elevation Myocardial Infarction (STEMI)","Heart Ventricles","Prognosis","Ventricular Dysfunction",[195,196,197,198,199,200,201],"ST Segment Elevation Myocardial Infarction","Cardiac Magnetic Resonance Imaging","Cardiac Strain Imaging","Machine Learning","Image Analysis","Survival Analysis","Multimodal Imaging","2025-07-09",{"date":204,"type":33},"2025-07-18",{"date":206,"type":33},"2014-01-01",{"date":208,"type":21},"2025-12-30",{"name":210,"class":40},"Chinese PLA General Hospital",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":53,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},"100593757","comparison-of-ultrasound-abbreviated-mri-with-and-without-hbp-as-modalities-for-hcc-surveillance-in-patients-with-high-risk-100593757","NCT07010588","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk","Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk: a Multi-centers, Randomized Controlled Open-label Trial","SHORT","Inclusion criteria\n\n* According to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) from department of medical administration, nation health commission of the People's Republic of China, with any one of the following high-risk factors for liver cancer: hepatitis B and\u002For C virus infection, excessive alcohol consumption, hepatic steatosis or metabolic dysfunction-associated liver disease, dietary exposure to aflatoxin B1, liver cirrhosis from other causes, or a family history of liver cancer, and an aMAP score (age⁃male⁃albi⁃platelets score) of 60-100 points.\n* Liver disease patients with no evidence of suspected liver cancer in any imaging examination (liver US, contrast-enhanced CT, or contrast-enhanced MRI) within the past six months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of previous liver cancer diagnosis.\n* Baseline screening at enrollment diagnosed with liver cancer.\n* Child-Pugh score ≥ 10 (class C).\n* History of other malignant tumors.\n* Pregnant or lactating women.\n* Clinically diagnosed severe heart\u002Flung disease or uncontrolled comorbidities, with investigator-judged life expectancy \\\u003C 2 years.\n* Glomerular filtration rate \\\u003C 50 mL\u002Fmin.\n* Inability to undergo (enhanced) MRI due to contraindications or relative contraindications.\n* Poor compliance or unsuitability for the clinical trial as judged by the investigator.","75 Years",{"count":221,"type":21},1389,[55],"Active surveillance in high-risk hepatocellular carcinoma (HCC) populations enables early detection of tumors. The currently recommended monitoring protocol involves biannual serum alpha-fetoprotein (AFP) testing combined with liver ultrasound (US) examinations. However, conventional US demonstrates limited sensitivity in detecting early-stage HCC lesions.\n\nMRI demonstrates high sensitivity in monitoring cirrhotic patients, but prolonged scanning time limits its routine clinical application. Several abbreviated MRI protocols have been developed for HCC detection, aiming to reduce acquisition time while improving early-stage HCC diagnostic accuracy.\n\nThe main question this clinical trial aims to answer is:\n\nCan non-contrast abbreviated MRI (NC-AMRI) and enhanced abbreviated MRI (E-AMRI) detect more early-stage HCC lesions compared to US-based screening? Researchers will randomly divide the participants into three groups in a 1:1:1 ratio, with different surveillance strategies, focused on early HCC detection rates.",[225,25,226],"Hepatocellular Carcinoma (HCC)","Randomized Controlled Trial",[228,229,230],"Hepatocellular carcinoma","magnetic resonance imaging","surveillance","2025-05-29",{"date":233,"type":33},"2025-06-08",{"date":235,"type":21},"2025-06",{"date":237,"type":21},"2030-06",{"name":99,"class":40},12,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":77,"sex":16,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":53,"phases":251,"briefSummary":253,"conditions":254,"keywords":260,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":41},"100570694","phase-4-multimodal-image-technologies-investigate-the-role-and-mechanism-of-probiotics-in-improving-rbd-with-parkinsons-disease-100570694","NCT06710574","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving Rapid Eye Movement Behavior Disorder with Parkinson's Disease","Inclusion Criteria:\n\nInclusion criteria for PD-RBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Patients with idiopathic Parkinson's disease, meeting the MDS clinical diagnostic criteria for Parkinson's disease (2015)\n* Modified Hoehn and Yahr stage of Parkinson's disease ≤ stage 3\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea\n* Stable condition of Parkinson's disease motor symptoms and RBD symptoms in the month prior to enrollment, with no adjustments to Parkinson's disease medications in the month prior to enrollment\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for iRBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea or restless legs syndrome\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for healthy subjects\n\n* Age between 40 and 80 years, age and gender matched with the above two groups of patients\n* Rapid Eye Movement Sleep Behavior Disorder screening questionnaire score ≤ 5, exclusion of RBD or obstructive sleep apnea based on polysomnography results\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24.\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* No severe constipation, not meeting the diagnostic criteria for Rome III chronic constipation; No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nExclusion Criteria:\n\nPD-RBD exclusion criteria:\n\n* Parkinsonism plus syndrome and secondary parkinsonism such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary parkinsonism\n* Taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases such as Alzheimer's disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with anxiety or depression and taking medication\n* Serious cardiovascular diseases (such as the American heart association heart function class for Ⅲ - Ⅳ of congestive heart failure, the 6 month history of myocardial infarction, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; Serum creatinine is higher than the upper limit of normal value 1. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients\n* Has a history of history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment\n* Refusal to participate in the study or inability to cooperate with the study investigator; The researchers judgment for doesn't fit into the group of patients.\n\nExclusion criteria for iRBD:\n\n* PD motor symptoms and parkinsonism were included in the PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\"\n* Into the group 2 months before taking any probiotics and prebiotics (including lactulose) or antibiotics\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; 3 month new cerebrovascular disease or severe cerebrovascular disease sequela, impact assessment;\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.);\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times;\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; Patients who were judged by the investigator to be ineligible for enrollment.\n\nHealthy subjects exclusion criteria:\n\n* Patients with Parkinson's disease motor symptoms and met the diagnosis of parkinsonism were included in PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\" 2) taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment; 1 month before the 3) into the group of Parkinson's disease medication adjustment; Benzodiazepines such as clonazepam and melatonin were taken within 1 month before enrollment. 4) combined with the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer's disease, malignant tumors, spinal cord lesions, epilepsy, autonomic disorders (urinary retention, urinary incontinence or orthostatic hypotension, blood pressure drop more than 30\u002F15 MMHG after 5 minutes of standing), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG; 9) known to the bifidobacterium triple viable capsules, bacillus licheniformis, or its accessories, and other allergies;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; The researchers judgment for doesn't fit into the group of patients.","40 Years","85 Years",{"count":250,"type":21},120,[252],"PHASE4","Rapid eye movement sleep behavior disorder (RBD) is important non-movement feature, and also the important risk factor of Parkinson's disease (PD). In our previous work, we found that the movement features and RBD of PD patients improved after taking probiotics. The later was not reported before and the mechanism not clear. To investigate its role and mechanism, we plan to enroll patients of PD-RBD, idiopathic RBD, and healthy control, collect data of multimodal image technology before and after probiotic treatment，including resting state functional MRI，1H-MRS，123I-MIBG; analyze these data with clinical features, including UPDRS -III score, RBD-HK score , as well as the bacteria abundance and level of glutamate，GABA in blood and stool. Then, construct PD mouse model by fecal transplantation of PD patient, give or not give mouse probiotics treatment, and detect the level of glutamate, GABA, and so on, as well as α-synuclein of each brain area of each group, to explore the role and mechanism of probiotics in improving RBD and movement disorder of PD.",[255,256,257,258,25,259],"Parkinson Disease","Movement Disorders","Rapid Eye Movement Sleep Behavior Disorder","Gut Microbiomes","Probiotic",[259,261,257,262],"Parkinson's disease","Multimodel Magnetic Resonance Imaging","2024-11-29",{"date":265,"type":33},"2024-12-02",{"date":267,"type":33},"2022-09-01",{"date":269,"type":21},"2025-06-30",{"name":271,"class":40},"Beijing Friendship Hospital"]